CALL FOR ABSTRACT: DEADLINE POSTICIPATA 20 AGOSTO 2022
L’invio degli abstract per il XXVIII Congresso Nazionale IMI, che si terrà nei giorni 30 settembre, 1 e 2 ottobre 2022, potrà essere effettuato esclusivamente attraverso l’invio per email.
|
L’apertura dell’abstract submission è prevista Il termine dell’invio dei contributi scientifici è stato posticipato Tale scadenza è assolutamente NON prorogabile. |
NON saranno accettati abstract inviati attraverso posta ordinaria o fax
POSTER SESSION
Epidemiologia, genetica e patogenesi
P101 Exposure to per- and polyfluoroalkyl substances (PFASs) and melanoma: a retrospective study on prognosis and histological features
Paolo Del Fiore et al.
P102 Incidence of cutaneous malignant melanoma by tumour thickness: do time trend differ between Emilia-Romagna and Sicily?
Silvia Mancini et al.
P103 Machine learning to predict overall short-term mortality in cutaneous melanoma
Claudia Cozzolino et al.
P104 Porocarcinoma: an epidemiological, clinical, and dermoscopic 20-year study
Flavia Silvestri et al.
P106 Primary cutaneous melanoma and COVID-19: a hospital-based study
Marco Brusasco et al.
P107 Risk factors in pediatric melanoma: a retrospective study of 39 cases
Cristian Fidanzi et al.
P108 Mitotic rate as predictive factor for positive sentinel lymph node in pT1 and pT2 melanomas
Cristian Fidanzi et al.
P109 Epidemiology of Merkel cell carcinoma in Tuscany (Italy), 2006 to 2021
Cristian Fidanzi et al.
Prevenzione e diagnosi
P201 Ultra-high frequency ultrasound and machine learning approaches for the differential diagnosis of melanocytic lesions
Teresa Oranges et al.
P202 Ultra-high frequency ultrasound in melanoma management: a new combined ultrasonographic-histopathological approach
Teresa Oranges et al.
P203 Clinicopathologic and dermoscopic features of 20 cases of Spark’s Nevus, a dermoscopic simulator of melanoma
Cesare Massone et al.
P205 Regression of atypical melanocytic nevi of genital type: a case report
Elena Biancamaria Mariotti et al.
P206 Recurrence-free survival prediction in melanoma patients by exploiting artificial intelligence techniques on melanoma whole slide images
Sabino Strippoli et al.
Classificazione patologica e molecolare
P301 Bright-field multiplex immunohistochemistry assay for tumor microenvironment evaluation in melanoma tissues
Filippo Ugolini et al.
P302 Melanoma multiomics under the magnifying glass of the Regina Elena and San Gallicano Institutes
Gennaro Ciliberto et al.
P303 Dermatopathology of Malignant Melanoma in the era of Artifi-cial Intelligence: a single institutional experience
Gerardo Cazzato et al.
P304 Semaphorins as predictive/prognostic factors and promising druggable target in melanoma
Matteo Brignone et al.
P305 The molecular characterization of Animal-Type Melanoma
Maria Chiara Sergi et al.
P306 BAP-1 inactivated tumors: a still unclear spectrum of melanocytic lesions.
Francesca Grasso et al.
P307 Multi-platform analysis of the heterogeneity of circulating melanoma cells and tumor DNA as useful tool to track disease evolution and targeted therapy response
Maria Chiara Scaini et al.
P308 Mutational status of superficial spreading and nodular primary melanomas in patients with disease recurrence toward the correlation with clinical, dermoscopic, and histological features: an IMI study (CARAMEL) - VINCITORE 1° PREMIO MIGLIOR POSTER
Maria Cristina Sini et al.
P309 Cutaneous angiosarcomas: molecular landscape beyond MYC deregulation
Andrea Ronchi et al.
Chirurgia
P401 Approach to melanocytic and non-melanocytic skin tumors. Building a multidisciplinary a regional cliinic
Andrea Lisa et al.
P402 Lymphadenectomy and its complications in III stage Melanoma
Francesca Tauceri et al.
P403 The role of radiotherapy and surgery to achieve complete response in metastatic melanoma: a multicentre retrospective analysis.
Marco Rubatto et al.
P404 Treatment of non-melanoma skin cancers with Mohs Micrographic Surgery and its variants: a single center experience - VINCITORE 3° PREMIO MIGLIOR POSTER
Federica Scarfì et al.
Terapia
P501 Melanoma brain metastases: a retrospective analysis of prognostic factors and efficacy of multimodal therapies
Valeria Internò et al.
P502 Treatment of periocular advanced basal cell carcinoma with Hedgehog pathway inhibitors: A single-center study and a new dedicated therapeutic protocol
Federico Venturi et al.
P503 Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design
Mario Mandalà et al.
P504 Extensive “halo naevi” phenomenon and regression of melanin during nivolumab treatment in metastatic melanoma: a predictor of a better outcome?
Gabriele Roccuzzo et al.
P505 Immune-related neuromuscular and cardiac adverse events: a retrospective, multicentre analysis and systematic review of case reports and series
Andrea Boutros et al.
P506 Cemiplimab for locally advanced cutaneous squamous cell carcinoma in elderly patients: real-life data from the Dermato-Oncology Unit of Trieste
Ludovica Toffoli et al.
P508 Rescue addition of ipilimumab to pembrolizumab or nivolumab in metastatic melanoma after resistance to anti-PD-1 monotherapy: a monocentric case series
Melissa Bersanelli et al.
P509 Local recurrence of melanoma treated with electrochemotherapy during immunotherapy: cases series of Central Tuscany Melanoma & Skin Cancer Unit and literature comparison
Isabella Ciardetti et al.
P510 Hedgehog Inhibitors (HHI) in the management of multiple BCCs in patients with nevoid basal cell carcinoma syndrome: a single centre evaluation of Sonidegib efficacy after Vismodegib discontinuation.
Federico Venturi et al.
P511 The importance of caregiving in patients with advanced basal cell carcinoma in treatment with hedgehog-pathway inhibitors: an observational prospective study
Luciana Trane et al.
P512 Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup.
Marco Rubatto et al.
P513 Patients with stage IV melanoma treated with immunotherapy for more than 2 years: is an end to treatment possible? - VINCITORE 2° PREMIO MIGLIOR POSTER
Marco Rubatto et al.
P514 Adjuvant immunotherapy in mucosal melanoma: an observational retrospective study from the Italian Melanoma Intergroup.
Paolo Fava et al.
P515 A case of cutaneous erosive Lichen Planus with mucosal involvement during Nivolumab treatment
Magliulo Manfredi et al.
P517 Patient-reported outcomes and quality of life in melanoma patients with asymptomatic brain metastases: results from the phase III NIBIT-M2 trial
Anna Maria Di Giacomo et al.
P518 Activity and safety of first line treatments for advanced melanoma: a network meta-analysis
Andrea Boutros et al.
P519 A retrospective observational multicenter study on skin toxicities induced by cemiplimab.
Matelda Medri et al.
P521 Exceptional response and long-term disease control following severe toxicities to BRAF inhibitors in a BRAF-V600E mutated melanoma patient
Luigi Cerbone et al.
P523 The Helicobacter pylori Protein HP-NAP: from a bacterium a new hope for the treatment of metastatic melanoma
Luigi Dall'Olmo et al.
QUOTE DI ISCRIZIONE (IVA 22% INCLUSA)
La quota di iscrizione include: accesso alle sessioni scientifiche, possibilità di ottenere i crediti ECM, materiale congressuale.
|
Categoria |
Importo |
|
Medici Soci IMI |
€ 300.00 |
|
Medici non Soci IMI |
€ 350.00 |
|
Specializzandi, non Medici |
€ 150.00 |
* E' prevista l'iscrizione giornaliera per un importo di € 150.00.
La Segreteria confermerà via email le iscrizioni regolarmente pervenute. Si raccomanda quindi di inserire una e-mail valida, al fine di confermare correttamente l'iscrizione.
Le iscrizioni risultanti prive del pagamento non saranno prese in considerazione.
Non sono previsti rimborsi per cancellazioni.
MODALITA' DI ISCRIZIONE
Per procedere con l’iscrizione cliccare sul seguente link https://iminazionale2022.it/ e seguire le istruzioni ivi riportate.
Sarà obbligatorio rispettare rigorosamente tutte le disposizioni governative vigenti in materia di contenimento e gestione dell’emergenza sanitaria.
Non potranno accedere al Congresso coloro che non si saranno previamente registrati con la modalità online sopra indicata. Chiusura tassativa iscrizioni il 27 settembre 2022.
CONTATTI
|
SEGRETERIA IMI Via XII Ottobre, 1 - 16121 Genova Tel. 010 8907874 Fax 010 8907901 Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.
|
Segreteria Organizzativa - Provider Age.na.s 1080 SOS S.r.l. - Scientific Organizing Service Via Salaria, 237 - 00199 Roma - Tel. / Fax 06 85 40 679 Cell. 335 8200986 - 333 1499382 Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo. - Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo. www.scientificorganizingservice.com
|